Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Eur Neuropsychopharmacol August 27, 2026 correction DOI: 10.1016/j.euroneuro.2026.113860 (opens in new tab)

Study at a glance

AI-extracted from the abstract

Topics	Depression Esketamine

Abstract

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study". Ther Adv Psychopharmacol May 19, 2026
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study". Eur Neuropsychopharmacol June 5, 2026
Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study". Eur Neuropsychopharmacol March 16, 2026
Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRD. Eur Psychiatry June 16, 2026
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2026 3 citations

Study at a glance

Abstract

Related reading